Integrated multi-omics analyses of oral squamous cell carcinoma reveal precision patient stratification and personalized treatment strategies
Cancer Letters · 2025-04 · 614 · 217482
DOI: 10.1016/j.canlet.2025.217482 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025-04. Verfasst von Chi-Sheng Wu und 29 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Medicine Research Center, Chang Gung University, Taoyuan City, 33302, Taiwan; Department of Otolaryngology-Head & Neck Surgery, Chang Gung …. Hauptthemen laut MEDLINE: Mouth Neoplasms, Precision Medicine, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chang Gung Memorial Hospital, National Human Genome Research Institute, National Cancer Institute.
Abstract (Originalsprache)
Oral cavity squamous cell carcinoma (OSCC), a leading subtype of head and neck cancer, exhibits high global incidence and mortality rates. Despite advancements in surgery and radiochemotherapy, approximately one-third of patients experience relapse. To improve current targeted and immunotherapy strategies for recurrent OSCC, we conducted multi-omics analyses on pretreatment OSCC samples (cohorts 1 and 2, n = 137) and identified A3A and EGFR, both at the RNA and protein levels, as inversely expressed markers for patient stratification and response prediction. Survival analysis demonstrated that elevated A3A or PD-L1 expression levels correlated to improved responses to anti-PD-1 therapy in patients (cohort 3a, n = 50, IHC). In contrast, high RRAS expression (cohort 4, n = 252, qRT-PCR) was significantly associated with OSCC recurrence. Cell-based experiments revealed that RRAS was involved in radiotherapy and cisplatin resistance through the EGFR/RRAS/AKT/ERK signaling pathway. In OSCC patient-derived xenograft (PDX) mouse models, treatments with cisplatin and cetuximab (anti-EGFR) effectively reduced tumor size in EGFR-high-derived (#34) but not A3A-high-derived (#22) PDX tumors. Our study demonstrated that A3A-high tumors were immune-hot and responsive to anti-PD-1 therapy, whereas EGFR-high tumors exhibited chr.7p11.2 gains and DNA repair alterations. Additionally, RRAS-high tumors were associated with OSCC recurrence via AKT and ERK phosphorylation and demonstrate improved clinical outcomes with cetuximab therapy (cohort 3b, n = 49, IHC). This study emphasizes the significance of A3A and EGFR expression levels in OSCC patient stratification and precision therapy, suggesting the use of anti-PD-1 or anti-EGFR treatments, respectively based on these biomarkers. Furthermore, RRAS emerges as a novel prognostic marker for local recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Medicine Research Center, Chang Gung University, Taoyuan City, 33302, Taiwan; Department of Otolaryngology-Head & Neck Surgery, Chang Gung Memorial Hospital at Linkou, Taoyuan City, 33305, Taiwan.
- Molecular Medicine Research Center, Chang Gung University, Taoyuan City, 33302, Taiwan; Department of Microbiology and Immunology, Chang Gung University, Taoyuan City, 33302, Taiwan; Division of Hematology-Oncology, Dep…
- Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, at Linkou, Taoyuan City, 33305, Taiwan; Division of Hematology-Oncology, Department of Internal Medicine, New Taipei Munici…
- Molecular Medicine Research Center, Chang Gung University, Taoyuan City, 33302, Taiwan.
- Molecular Medicine Research Center, Chang Gung University, Taoyuan City, 33302, Taiwan; Department of Neurosurgery, Chang Gung Memorial Hospital at Linkou, Taoyuan City, 33305, Taiwan; Genomic Medicine Core Laboratory,…
- Department of Pathology, Chang Gung Memorial Hospital at Linkou, Taoyuan City, 33305, Taiwan; School of Medicine, National Tsing-Hua University, Hsinchu, 300044, Taiwan; Institute of Stem Cell and Translational Cancer R…
Förderung
- Chang Gung Memorial Hospital
- National Human Genome Research Institute
- National Cancer Institute
- Ministry of Education
- National Science and Technology Council
- Chang Gung University
- Ministry of Science and Technology, Taiwan
Zitieren
APA
Wu, C. S., Li, H. P., Hsieh, C. H., Lin, Y. T., Yi-Feng Chang, I., Chung, A. K., Huang, Y., Ueng, S. H., Hsiao, Y. C., Chien, K. Y., Luo, J. D., Chen, C. H., Liao, W. C., Hung, J. L., Yuan, S. N., OuYang, C. N., Chiang, W. F., Chien, C. Y., Chuang, H. C., …, & Chang, Y. S. (2025). Integrated multi-omics analyses of oral squamous cell carcinoma reveal precision patient stratification and personalized treatment strategies. Cancer Letters, 614, 217482. https://doi.org/10.1016/j.canlet.2025.217482
Vancouver
Wu CS, Li HP, Hsieh CH, Lin YT, Yi-Feng Chang I, Chung AK, et al. Integrated multi-omics analyses of oral squamous cell carcinoma reveal precision patient stratification and personalized treatment strategies. Cancer Letters. 2025;614:217482. doi:10.1016/j.canlet.2025.217482
BibTeX
@article{Wu2025,
author = {Wu, Chi-Sheng and Li, Hsin-Pai and Hsieh, Chia-Hsun and Lin, Yu-Tsun and Yi-Feng Chang, Ian and Chung, An-Ko and Huang, Yenlin and Ueng, Shir-Hwa and Hsiao, Yung-Chin and Chien, Kun-Yi and Luo, Ji-Dung and Chen, Chia-Hua and Liao, Wei-Chao and Hung, Jui-Lung and Yuan, Sheng-Ning and OuYang, Chun-Nan and Chiang, Wei-Fan and Chien, Chih-Yen and Chuang, Hui-Ching and Chu, Lichieh Julie and Liu, Hsuan and Yang, Chia-Yu and Robles, Ana I and Rodriguez, Henry and Lin, Hsi-Hsien and Yang, Huang-Yu and Hsueh, Chuen and Chang, Kai-Ping and Yu, Jau-Song and Chang, Yu-Sun},
title = {Integrated multi-omics analyses of oral squamous cell carcinoma reveal precision patient stratification and personalized treatment strategies},
journal = {Cancer Letters},
year = {2025},
volume = {614},
pages = {217482},
doi = {10.1016/j.canlet.2025.217482}
}
EUVIMED